Purchase of 4,000 doses of the FDA approved HPV6/11/16/18/31/33/45/52/58 virus-like particles with alum-adjuvant vaccine (gardasil-9) for the one dose trial.

Ended Purchase Order Awarded Last action

Contract number
HHSN261201800084P
Awardee
Awarding agency
Obligated
$467,200

Award facts

Opportunity
Contract value 100% obligated
$467,200.00 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
NAICS code
325412 Pharmaceutical Preparation Manufacturing
PSC
6505 Drugs And Biologicals
Set-aside
No set-aside
Competition
Not Competed · 1 offer Only One Source
Pricing
Firm Fixed Price
Place of performance
Bethesda, MD 20892, USA

Award details come from SAM.gov/FPDS.

About this award

Written by GovTribe AI ·

The National Cancer Institute awarded a purchase order to Merck Sharp & Dohme LLC for $467,200 on December 19, 2017, for 4,000 doses of Gardasil-9 HPV vaccine (FDA-approved 9-valent virus-like particles formulation with alum adjuvant) to support a one-dose clinical trial. Performance is located in Bethesda, Maryland. The order carries firm fixed pricing with an ultimate completion date of January 15, 2018. No set-aside category was used.

Quick answers

Who was awarded contract HHSN261201800084P?

HHSN261201800084P was awarded to Merck Sharp & Dohme LLC by National Cancer Institute (National Institutes of Health) on December 19, 2017.

How much is contract HHSN261201800084P worth?

The government has obligated $467,200 on HHSN261201800084P.

Was contract HHSN261201800084P competed?

The extent of competition for HHSN261201800084P was not competed. The government received 1 offer.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award
Try for free Login